Neuropeptides and Cognitive Neuroscience
Neuropeptides are molecules which have a signalling function and thus affect cell communication in the entire nervous system; unlike conventional neurotransmitters, a number of neuropeptides are produced and released in a way that enables them to have an effect over a wider spatial and temporal range.
Research has found neuropeptide systems in those parts of the brain which are associated with learning, memory and the processing of emotions, such as the hippocampus, the amygdala and the basal forebrain. These systems interact with the existing neurotransmitter systems involving GABA, glutamate, acetylcholine and other signalling pathways.
Neuropeptides are therefore useful for the study of how molecular signalling affects synaptic function and neural plasticity.
The question raised by the research is therefore more specific than asking whether a peptide "improves cognition"; it instead allows researchers to look at which receptor is involved, which intracellular pathway is altered, which part of the brain is affected and how the neuronal response measured changes under the specified experimental conditions.
Peptide Signalling and the Brain
Peptide signalling within the central nervous system is very diverse.
Certain peptides function mainly as neuromodulators, whereas others are involved in the communication between neurons, glial cells and peripheral tissues. The effects of these peptides can vary according to the receptor subtype, the anatomical location, the level of neuronal activity and the physiological state of the experimental model.
Neuropeptide Y, vasoactive intestinal peptide, somatostatin, galanin and a number of other peptide systems have all been studied with regard to learning, memory and neural plasticity; research shows that these systems are able to interact with conventional neurotransmitter pathways rather than functioning as separate signalling systems.
When one is interpreting research into peptides, the fact that this behaviour occurs at the network level is something that should be taken into account.
Neuropeptide Receptors and Signal Transduction
The receptor interactions have a substantial effect on the biological activity of a peptide.
A large number of neuropeptide receptors are members of the family of G-protein-coupled receptors. When the receptor is activated it can affect intracellular signalling by means of pathways that involve cyclic AMP, phospholipase C, calcium mobilisation, protein kinases and changes in gene expression.
It is therefore possible for the same peptide to give rise to different cellular responses according to the receptor subtype that is present.
For instance, research on neuropeptide Y has shown that the Y1 and Y2 receptor systems have different roles in various experimental models concerned with memory, and the effects reported also depend on the type of memory being studied and the phase of the behavioural process under examination.
For laboratory research, receptor subtype and tissue distribution are therefore important variables rather than just minor technical details.
Neuropeptides and Synaptic Plasticity
Research into learning and memory often looks at synaptic plasticity, which is the ability of neural connections to alter in response to activity.
Peptide signalling can affect this process by means of its interaction with neurotransmitter receptors, intracellular kinase pathways, calcium signalling and transcriptional mechanisms.
Such interactions may take place at a number of levels; for example, a peptide can affect the release of neurotransmitters, influence receptor activity or alter intracellular signalling in the neuron which receives it.
Research usually looks at molecular markers together with functional or behavioural endpoints. By examining both levels it is possible to find out whether an observed change is linked to a particular signalling pathway or merely indicates a downstream correlation.
Neuropeptide Y as a Research Model
Neuropeptide Y, or NPY, is a good example of how complex peptide signalling is in neuroscience.
NPY is widely present in the central nervous system and has been studied in connection with neurotransmission, neuroplasticity and memory; research shows that its effects can differ depending on the receptor subtype, the brain region, the type of memory and the experimental stage.
The fact that it varies is important from a scientific point of view.
The fact that NPY 'enhances memory' would fail to take into account the differences between acquisition, consolidation and retention as well as the various receptor populations involved.
A better way of describing the research is to state which NPY receptor is being studied, where in the anatomy the investigation takes place, and what specific behaviour or molecular endpoint is being measured.
Semax and Neurotrophic Signalling Research
Semax is a synthetic peptide which has been the subject of investigation in the field of experimental neuroscience because it is derived from a sequence related to ACTH.
Research on rats has looked at Semax in connection with the brain-derived neurotrophic factor, or BDNF, system. In one study alterations were found in both BDNF and TrkB expression and phosphorylation in the hippocampus after experimental exposure.
It serves as an example of peptide research being able to go beyond merely making behavioural observations and instead carry out molecular analysis.
BDNF and its receptor TrkB are significant areas of study in the field of neuroscience since they are involved in neuronal signalling and plasticity; when a study focusing on this system is carried out, values such as gene expression, protein abundance or receptor phosphorylation can yield information about the mechanisms involved.
The conclusions drawn from the experiment should be linked to the experimental model since the results obtained from experiments on the hippocampus of rodents do not in themselves prove that there are effects on human cognition.
Selank and GABAergic Signalling Research
Selank is yet another instance of a peptide being studied via a specific neurotransmitter system.
Experimental research has looked into its connection with GABAergic signalling. A study found changes in the expression of genes associated with GABAergic neurotransmission and other neuronal signalling systems in the frontal cortex of rats after experimental administration had been given.
Research into receptor binding has looked at whether there are any interactions between Selank and the GABA-related binding systems.
This shows that receptor and signalling studies are useful when assessing peptide neuroscience, since instead of just calling a compound a "cognitive peptide", researchers can examine its relationship with specific molecular systems.
The evidence must also be understood in the light of its origin since the results of cellular studies, receptor-binding studies and animal experiments address different questions and therefore should not be regarded as equivalent types of evidence.
GABA Signalling and Cognitive Research
GABA is the main inhibitory neurotransmitter in the brain and has a significant role in the regulation of neuronal activity.
It has been found that tonic GABA transmission can affect synaptic transmission and plasticity by means of extrasynaptic GABA-A receptors, and these mechanisms have also been studied in connection with cognitive processes.
This is important background information for research into peptides and GABAergic pathways.
The fact that an experimental peptide affects either the activity of GABA-related receptors or gene expression is merely a molecular observation within the wider inhibitory signalling network and does not mean it should be taken as proof of a specific cognitive outcome.
Peptide Signalling and BDNF
BDNF is also one of the main areas of study in neuroscience concerning neural plasticity.
Research into peptides such as Semax has looked at whether experimental exposure leads to changes in BDNF or TrkB-related signalling in particular areas of the brain.
Measurements related to BDNF can involve gene expression, the amount of protein, receptor phosphorylation and downstream signalling activity.
These endpoints are useful since they offer molecular information which can be compared across different experimental groups. Yet a rise or fall in a molecular marker does not necessarily mean that there has been a corresponding change in learning, memory or other complex behaviours.
It is important to make the distinction between molecular evidence and functional evidence when interpreting peptide neuroscience.
Experimental Models Used in Peptide Neuroscience
The study of neuropeptides involves a number of different levels of experimental investigation.
It is possible to use in vitro models to study receptor binding, intracellular signalling, gene expression or neuronal responses. Although these systems allow for control over the various experimental factors they are unable to replicate the complete complexity of a whole nervous system.
Using animal models, researchers are able to study peptide signalling in specific brain areas and in the integrated neural circuits. At the same time, behavioural studies can look at learning and memory patterns together with biochemical measurements.
Human research constitutes another kind of evidence, but the results obtained from such studies must be differentiated from preclinical observations.
A review of the role of neuropeptides in learning and memory has pointed out that up to now the experimental literature has mainly depended on studies of rodents, there being considerably fewer studies involving humans.
When assessing a research claim, the model is just as important as the peptide.
Common Endpoints in Cognitive Peptide Research
Different experiments need different endpoints.
Molecular studies can look at receptor binding, phosphorylation, gene expression and protein abundance or intracellular signalling.
Cellular studies are able to examine neuronal activity, the release of neurotransmitters, receptor trafficking or synaptic responses.
Animal studies can include measurements of behaviour involving learning, memory, exploration or stress-related scenarios.
One should not consider these endpoints to be interchangeable.
For instance, a change in BDNF expression constitutes a molecular finding while a change in a behavioural memory test is a functional observation; in order to establish a relationship between the two an appropriate experimental design is needed rather than assuming that one automatically predicts the other.
Why Brain Region Matters
The anatomical distribution has a strong influence on peptide signalling.
The hippocampus plays a central role in many areas of research concerning learning and memory, and the amygdala is closely linked with emotional and associative processing. The prefrontal cortex is involved in executive and working-memory functions.
A peptide receptor appearing in one area could therefore give rise to a different experimental response when the same receptor is found in another area.
Research into NPY shows that the effect varies depending on the brain region and the memory paradigm.
That is why neuroscience studies should focus on identifying the specific brain area rather than referring to peptide activity as having a general effect on the brain.
Why Dose, Timing and Exposure Conditions Affect Interpretation
The results of experimental peptide research depend on the exposure conditions.
The measured response can be affected by concentration, the length of exposure, the timing in relation to the behavioural test, the stability of the peptide and the experimental model.
It is especially important when drawing comparisons between the results of different studies since two experiments involving the same peptide might yield different observations because they employed different models, endpoints or experimental conditions.
Hence, findings from individual studies should not be taken automatically as representing a direct head-to-head comparison.
The appropriate question when writing a research article is not whether a peptide is 'stronger' or 'better', but rather which biological pathway was studied and under what experimental conditions.
Comparing Peptide Research Without Overstating the Evidence
Peptide neuroscience includes several different research areas.
| Research variable | |
|---|---|
| Molecular target | The receptor, the neurotransmitter system, or the intracellular pathway or neurotrophic signalling system under investigation. |
| Brain region | The hippocampus, the cortex, the amygdala, the hypothalamus or some other specified neural structure. |
| Experimental model | A receptor-binding assay, using cultured cells, isolated neural tissue, an animal model or a human study. |
| Primary endpoint | The expression of genes, the activity of receptors, protein signalling, neuronal activity or behavioural measurement. |
| Mechanistic evidence | Evidence showing that exposure to peptides is linked to a specific molecular or cellular pathway under controlled conditions. |
A comparison of this type contains more scientific information than simply classifying the compounds according to a desired effect such as "focus", "memory" or "brain performance".
What Current Research Can and Cannot Establish
Research currently shows that peptide signalling is relevant to a number of areas in neuroscience, such as neurotransmission, receptor regulation, neural plasticity and processes related to memory.
The evidence, on the other hand, differs a great deal among peptide systems.
The fact is that an experiment involving receptor binding cannot prove a behavioural effect. A study carried out in cell culture does not replicate the complexity of a complete nervous system. Likewise, an animal behaviour study does not necessarily mean that there is a corresponding effect in humans.
This evidence hierarchy is particularly important for research involving compounds marketed online under broad terms such as "nootropic peptides" or "cognitive peptides."
Scientific interpretation should remain tied to the actual experiment.
Research Use Only
Peptide neuroscience remains an active area of laboratory research involving receptor pharmacology, neurotransmitter systems, neural plasticity and molecular signalling.
The compounds discussed in this article are presented in a research context only. Experimental findings should not be interpreted as evidence of clinical efficacy, safety, cognitive enhancement or suitability for human use.
Direct SARMs provides research-focused peptide materials for laboratory investigation. Researchers interested in peptide compounds can visit the Peptide Category to review available research materials and associated technical information.
All products are intended for research and laboratory use only and are not for human or animal consumption.
FAQs
References
- Gøtzsche CR, Woldbye DP. The role of NPY in learning and memory. Neuropeptides. 2016 Feb;55:79-89. doi: 10.1016/j.npep.2015.09.010. Epub 2015 Oct 3. PubMed ↗
- Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006 Oct 30;1117(1):54-60. doi: 10.1016/j.brainres.2006.07.108. Epub 2006 Sep 22. PubMed ↗
- Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016 Feb 18;7:31. doi: 10.3389/fphar.2016.00031. PubMed ↗
- Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. doi: 10.2174/0929866525666180925144642. PubMed ↗
- Koh W, Kwak H, Cheong E, Lee CJ. GABA tone regulation and its cognitive functions in the brain. Nat Rev Neurosci. 2023 Sep;24(9):523-539. doi: 10.1038/s41583-023-00724-7. Epub 2023 Jul 26. PubMed ↗
- Autio J, Stenbäck V, Gagnon DD, Leppäluoto J, Herzig KH. (Neuro) Peptides, Physical Activity, and Cognition. J Clin Med. 2020 Aug 10;9(8):2592. doi: 10.3390/jcm9082592. PubMed ↗